Dual-functional melatonin releasing device loaded with PLGA microparticles and cyclodextrin inclusion complex for osteosarcoma therapy


ÇETİN ALTINDAL D. , Gumusderelioglu M.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, cilt.52, ss.586-596, 2019 (SCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 52
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.jddst.2019.05.027
  • Dergi Adı: JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
  • Sayfa Sayıları: ss.586-596

Özet

The aim of this study is to develop a scaffold-based device in which both osteoinductive and anticarcinogenic properties of melatonin can be combined for osteosarcoma therapy. While a high melatonin concentration and fast release are needed to achieve an anticancer effect, a low melatonin concentration and long-term release are necessary for bone regeneration. Long-term controlled release of melatonin was provided by the incorporation of melatonin-loaded poly(lactic-co-glycolic acid) (PLGA) microparticles into the chitosan/hydroxyapatite (chitosan/HAp) scaffolds. This system showed a biphasic melatonin release-pattern with a burst release within 24 h, and then, a sustained release for 40 days that resulted into similar to 40-70 mu M concentration. Preosteoblastic MC3T3-E1 cells were cultured on this 3D device, and released melatonin caused increase in the expressions of osteogenic differentiation markers. For the inhibition of MG-63 human osteosarcoma cells, a melatonin/2-hydroxypropyl-beta-cyclodextrin (HP beta CD) inclusion complex was prepared by microwave technology to load a high amount of melatonin and provide fast release. Melatonin/HP beta CD inclusion complex was incorporated into the chitosan/HAp scaffolds and loaded melatonin was rapidly released within 5 h and inhibited the proliferation of MG-63 cells in the G(0)/G(1) phase. In conclusion, this melatonin-releasing scaffold-based device including melatonin-loaded PLGA microparticles and melatonin/HP beta CD inclusion complex can be considered as a promising system for osteosarcoma therapy.